

Attorney Docket No.: KBI-0004
Inventors: Ranganathan et al.
Serial No.: 09/855,346
Filing Date: May 15, 2001
Page 2

degrading microorganism with high alkaline pH stability and high urease activity, said composition being microencapsulated or enteric coated with a material designed to deliver the probiotic, a prebiotic, and ammoniaphilic urea degrading microorganism to their site of action in relatively native form without binding of various digestive materials to the sorbents prior to reaching the target region, and prevent infection of a patient from the ammoniaphilic urea degrading microorganism.

3. (amended) The pharmaceutical composition of claim 2 where the water absorbent is selected from the group consisting of locust bean gum, psyllium fiber, guar gum and zeolite.

5. (amended) The pharmaceutical composition of claim 4 wherein the sorbent for inorganic phosphate is selected from the group consisting of aluminum hydroxide gel, calcium hydroxide gel and magnesium hydroxide gel and the specific uremic solute adsorbent is activated charcoal.

7. (amended) The pharmaceutical composition of claim 1 wherein the prebiotic is selected from the group consisting of fructan oligosaccharide and araban oligosaccharide.

8. (amended) The pharmaceutical composition of claim 1

Attorney Docket No.: KBI-0004
Inventors: Ranganathan et al.
Serial No.: 09/855,346
Filing Date: May 15, 2001
Page 3

wherein the ammoniaphilic bacteria is selected from the group consisting of *Bacillus pasteurii*, *Sporosarcina ureae*, *Bacillus* species and *Lactobacillus* species KB-I.

10. (amended) A pharmaceutical composition comprising a probiotic, a prebiotic, an ammoniaphilic urea degrading microorganism with high alkaline pH stability and high urease activity, a water absorbent, a sorbent for inorganic phosphate and an adsorbent for specific uremic solutes other than urea, said composition being microencapsulated or enteric coated with a material designed to deliver the probiotic, a prebiotic, and ammoniaphilic urea degrading microorganism to their site of action in relatively native form without binding of various digestive materials to the sorbents prior to reaching the target region, and prevent infection of a patient from the ammoniaphilic urea degrading microorganism.

REMARKS

Claims 1-16 are pending in the instant application. Claims 1-10 have been rejected, Claims 11-16 have been withdrawn from consideration. Claims 1, 3, 5, 7, 8 and 10 have been amended. No new matter has been added. Reconsideration is respectfully requested in light of these amendments and the following remarks.